Catalyst Biosciences’ Program Hits Financial Milestone

Catalyst Biosciences shares were up over 4% pre-market Thursday after the company said it has achieved a financial milestone under its collaboration with ISU Abxis.

In June, the first patient and cohort were enrolled in a phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B, which triggered the milestone payment to Catalyst. ISU Abxis and Catalyst plan to have top-line data from the clinical trial by the end of 2017.

Leave a Comment